Most reported effects trace back to the axis being stimulated rather than to any individual compound. Fluid retention, joint pain, carpal tunnel symptoms, and reduced insulin sensitivity recur across the literature on raising growth hormone. On top of that sit compound-specific signals that FDA has named, and, for compounded preparations, quality questions that have nothing to do with pharmacology.
Dr. Christopher S. Raffo, MD, Orthopedic Surgery
The effects that come from the axis itself
Randomized trials of growth hormone in healthy older adults give the clearest picture, because the peptides are attempts to produce the same hormone response. In that pooled evidence, participants receiving growth hormone were significantly more likely than controls to experience soft tissue swelling, joint pain, carpal tunnel syndrome, and gynecomastia. They were somewhat more likely to develop impaired fasting glucose or diabetes. Fat mass fell and lean mass rose by roughly two kilograms each, with no significant change in body weight.
Trials in younger, physically fit adults reported a similar adverse pattern. Soft tissue swelling and fatigue were more frequent in treated participants, and exercise lactate ran higher in most studies that measured it, while strength and exercise capacity did not improve.
Swelling in the hands and feet, aching joints, and numbness or tingling in the fingers are therefore the everyday complaints to expect if the axis is being pushed. They tend to be dose-related and tend to ease if stimulation is reduced.
Glucose is the effect that deserves the most attention
The metabolic signal is the one with a consistent trail behind it. In a two-year randomized trial of the oral ghrelin mimetic MK-677 in healthy older adults, fasting glucose rose by around 5 mg/dL and insulin sensitivity decreased. Cortisol rose modestly. The most frequent complaints were increased appetite, which subsided over months, and transient mild swelling of the lower legs with muscle pain.
A review of growth hormone secretagogues in humans reached the same conclusion from a wider set of studies: the agents appeared generally tolerated in the short term, with the recurring concern being higher blood glucose driven by reduced insulin sensitivity. That review also noted how few long-term controlled studies exist, and that cancer incidence and mortality have not been assessed over meaningful timeframes.
The gap is easier to see next to a drug class that has been studied properly. GLP-1 medications carry documented adverse effect profiles because they are approved and trialed, and telehealth providers such as Ro, Henry Meds, and LillyDirect publish patient-facing summaries drawn from that labeling. The HealthRX overview of GLP-1 side effects is the kind of reviewed safety information that simply has no counterpart for a compounded growth hormone peptide, where the effect list is inferred from studies of the hormone rather than the product itself.
Compound-specific signals FDA has documented
FDA maintains a list of bulk drug substances nominated for compounding that may present significant safety risks, and several compounds sold in this category appear on it.
Ibutamoren mesylate is listed for potential congestive heart failure risk, citing a randomized placebo-controlled trial in patients recovering from hip fracture that was terminated early over a possible heart failure signal. GHRP-2 is listed with reports of serious adverse events including increased insulin requirement, infection, pancreatitis, and deaths among critically ill study subjects, with causality not established. GHRP-6 is listed with concerns about cortisol effects and rising blood glucose from decreased insulin sensitivity. Ipamorelin acetate is listed partly because a published study identified serious adverse events including death when it was given intravenously for gastric motility, and partly because FDA has no safety information for other injectable routes. CJC-1295 appears among withdrawn nominations, with FDA describing serious adverse events including increased heart rate and a systemic vasodilatory reaction.
Every one of those entries also raises immunogenicity risk from aggregation and peptide-related impurities. That is a manufacturing and characterization concern rather than a dose concern, and it does not resolve by taking less.
What a monitoring plan should cover
| What is watched | Why it is on the list |
|---|---|
| Fasting glucose and HbA1c | The most consistently reported metabolic effect across this class |
| IGF-I | Shows whether the axis moved and whether it moved too far |
| Swelling in hands, feet, and lower legs | Common, dose-related, and an early sign of overstimulation |
| Joint pain and hand numbness | Carpal tunnel symptoms were among the more frequent adverse events |
| Blood pressure and heart rate | Cardiovascular effects have been reported with some compounds |
| Injection site condition | Local reactions and infection risk with any injected preparation |
| Whether the stated goal is moving | Distinguishes a treatment from an open-ended subscription |
What the one approved product reports
Tesamorelin carries an approved label, so its adverse effect data is public and reviewed. In a randomized trial in adults with HIV and abdominal fat accumulation, fasting glucose rose significantly in the treated group at two weeks, though the difference was not significant at six months. The prescribing information states that long-term cardiovascular safety has not been established, and that the product is not indicated for weight loss management.
That is what a reviewed safety picture looks like: specific, bounded, and honest about what is unknown. No other compound in this category has one.
Questions worth raising before starting
Ask which laboratory values will be drawn at baseline and how often they will be repeated. Ask what change in a value would prompt stopping rather than adjusting. Ask who to contact when swelling, joint pain, or hand numbness appears, and how quickly a reply should be expected. Ask which pharmacy prepares the medication and whether it operates as a 503A compounder or a 503B outsourcing facility.
Ask what happens to the prescription if nothing measurable improves after several months, because a plan with no stopping rule tends not to stop. Continuity questions of that kind are reasonable to put to a provider before the first shipment rather than after a problem appears, and physician-supervised services such as FormBlends, Defy Medical, and Marek Health can be compared directly on how specifically they answer them.
Frequently asked questions
Are these safer than injected growth hormone?
The argument is that pulsatile release preserves feedback and avoids sustained high levels. It is plausible and not proven. Long-term controlled safety data for secretagogues is scarce, and the metabolic effects that concern people about growth hormone appear in secretagogue studies too.
Why does swelling happen?
Growth hormone promotes sodium and water retention, which shows up as puffy hands and feet or tight rings. It was among the most consistently reported adverse events in randomized trials and generally tracks with how hard the axis is being stimulated.
Should blood sugar be tested even without diabetes?
Testing is reasonable given the pattern in the evidence. Randomized data on both growth hormone and MK-677 recorded rising glucose measures and falling insulin sensitivity in people who started without diabetes, which is precisely the group a baseline value would otherwise miss.
What symptoms warrant prompt contact with the prescriber?
Persistent hand numbness or weakness, swelling that does not settle, new or worsening shortness of breath, chest symptoms, severe abdominal pain, and signs of infection at an injection site. Each of these has appeared in safety reporting for compounds in this category.
Does compounded status affect the side effect profile?
It adds uncertainty rather than a distinct set of effects. Compounded preparations are not FDA-approved and are not reviewed for quality before sale, and FDA has flagged immunogenicity and impurity concerns for several of these substances specifically.
